# Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C

> **NCT05240521** · NA · UNKNOWN · sponsor: **Devintec Sagl** · enrollment: 60 (estimated)

## Conditions studied

- Irritable Bowel Syndrome With Constipation (IBS-C)

## Interventions

- **OTHER:** ARM A
- **OTHER:** ARM B

## Key facts

- **NCT ID:** NCT05240521
- **Lead sponsor:** Devintec Sagl
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-01
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05240521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05240521, "Efficacy and Safety, Tolerability of GA-AT0119 in IBS-C". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05240521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*